Evidence map›Paper›PMID 26542707›Full record

ReviewReviews in endocrine & metabolic disorders2015

The role of prolactin in andrology: what is new?

Giulia Rastrelli, Giovanni Corona, Mario Maggi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 84 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Acquired hypoprolactinemia in men, possible phenotype.Reviews in endocrine & metabolic disorders · 2024
    Review
  8. Review
  9. Review
  10. Diagnosis of hypoprolactinemia.Reviews in endocrine & metabolic disorders · 2024
    Review
  11. Drug induced hypoprolactinemia.Reviews in endocrine & metabolic disorders · 2024
    Review
  12. The molecular basis of hypoprolactinaemia.Reviews in endocrine & metabolic disorders · 2024
    Review
  13. Review
  14. Article
  15. Cognition and psychological wellbeing in hypopituitary patients.Reviews in endocrine & metabolic disorders · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Erectile dysfunction as a marker of endocrine and glycemic disorders.Journal of endocrinological investigation · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Giulia RastrelliSexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy.
Giovanni CoronaSexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy.
Mario MaggiSexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy. mario.maggi@unifi.it.
University of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prolactin (PRL) has been long deemed as a hormone involved only in female reproduction. However, PRL is a surprising hormone and, since its identification in the 1970s, its attributed functions have greatly increased. However, its specific role in male health is still widely unknown. Recently, low PRL has been associated with reduced ejaculate and seminal vesicle volume in infertile subjects. In addition, in men consulting for sexual dysfunction, hypoprolactinemia has been associated with erectile dysfunction and premature ejaculation, findings further confirmed in the general European population and infertile men. Several metabolic derangements, recapitulating metabolic syndrome, have also been associated with low PRL both in men with sexual dysfunction and from the general European population. In men with sexual dysfunction, followed-up for more than 4 years, low PRL was identified as an independent predictor of the incidence of major adverse cardiovascular events. Finally, an association with anxiety or depressive symptoms has been found in men with sexual dysfunction and from the general European population. While a direct role for impaired PRL function in the pathogenesis of these reproductive, sexual, metabolic and psychological disorders is conceivable, the possibility that low PRL is a mirror of an increased dopaminergic or a decreased serotonergic tone cannot be ruled-out. Hyperactivity of the dopaminergic system can explain only a few of the aforementioned findings, whereas a hypo-serotonergic tone fits well with the clinical features associated with low PRL, and there is significant evidence supporting the hypothesis that PRL could be a mirror of serotonin in the brain.

Indexed as

AndrologyAnimalsBrain ChemistryCardiovascular DiseasesDopamineEjaculationErectile DysfunctionHumansInfertility, MaleMaleMental DisordersProlactinReproductionSeminal VesiclesSerotoninSexual Dysfunction, PhysiologicalDopamineProlactinSerotoninManMetabolismProlactinSerotoninSexuality

Identifiers

PMID26542707
OpenAlexW2193813944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.